GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioAtla Inc (NAS:BCAB) » Definitions » COGS-to-Revenue

BioAtla (BioAtla) COGS-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is BioAtla COGS-to-Revenue?

BioAtla's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was $0.00 Mil.

BioAtla's COGS to Revenue for the three months ended in Mar. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. BioAtla's Gross Margin % for the three months ended in Mar. 2024 was N/A%.

BioAtla COGS-to-Revenue Historical Data

The historical data trend for BioAtla's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioAtla COGS-to-Revenue Chart

BioAtla Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial - - - - -

BioAtla Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BioAtla COGS-to-Revenue Calculation

BioAtla's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

BioAtla's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioAtla  (NAS:BCAB) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

BioAtla's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

BioAtla COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of BioAtla's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

BioAtla (BioAtla) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioAtla Inc (NAS:BCAB) » Definitions » COGS-to-Revenue
Comparable Companies
CDTX CAPR CTMX MDWD ELYM CSBR OMER VTGN OMGA AVRO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
11085 Torreyana Road, San Diego, CA, USA, 92121
Website
https://www.bioatla.com
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise Mecbotamab vedotin, Ozuriftabmab vedotin, BA3071, and Bispecific antibody programs.
Executives
Sylvia Mcbrinn director
Short Jay M Phd director, 10 percent owner, officer: Chief Executive Officer C/O DIVERSA CORPORATION, 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Christian Vasquez officer: See Remarks 121 E. PALOMAR STREET, CHULA VISTA CA 91911
Lawrence Steinman director 10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Eddie Williams director 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Scott Andrew Smith director, officer: President C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Eric Sievers officer: Chief Medical Officer 11085 TORREYANA ROAD, SAN DIEGO CA 92121
Richard A Waldron officer: Chief Financial Officer 901 MARINERS ISLAND BLVD STE.205, SAN MATEO CA 94404
Guy Levy director, 10 percent owner C/O SOLEUS PRIVATE EQUITY GP I, LLC, 104 FIELD POINT ROAD, 2ND FLOOR, GREENWICH CT 06830
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Soleus Pe Gp I, Llc 10 percent owner 104 FIELD POINT ROAD, 2ND FLOOR, GREENWICH CT 06830
Himalaya Parent Llc 10 percent owner 11085 TORREYANA ROAD, SAN DIEGO CA 92121
Susan Moran director 1232 RICHARDSON AVE, LOS ALTOS CA 94024
Carolyn Anderson Short 10 percent owner, officer: See Remarks 11085 TORREYANA ROAD, SAN DIEGO CA 92121
Priyanka Belawat director C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142